[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:pik3ca-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"PIK3CA Gene",29,27,[8,16,23,30,36,42,48,54,60,67,73,79,86,92,98,104,110,116,122,128,134,140,146,152,158,164,170,176,183],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06638307","A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer",[12],"Phase 1","RECRUITING","2026-08-26T02:19:16.454910Z","2026-07-05T05:32:16.765634Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06757634","Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)",[20],"Phase 3","2026-08-26T02:15:54.846520Z","2026-07-05T05:32:16.692648Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT03424005","A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer",[27],"Phase 1\u002FPhase 2","2026-08-26T02:15:26.669629Z","2026-06-17T19:21:16.689089Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT05455619","Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+\u002FHer2- Breast Cancer",[27],"2026-08-26T02:16:28.221034Z","2026-05-05T02:47:14.270026Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT05683418","A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer",[12],"2026-08-26T02:18:24.494016Z","2026-05-05T02:43:28.868587Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT06790693","A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4\u002F6 Inhibitor and Letrozole vs Placebo + CDK4\u002F6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer",[20],"2026-08-26T02:17:39.857430Z","2026-05-05T02:43:28.738059Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT04802759","A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer",[27],"2026-08-26T02:18:25.327036Z","2026-05-05T02:43:28.562382Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT05216432","First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +\u002F- a CDK4\u002F6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer",[12],"2026-08-26T02:19:26.493949Z","2026-05-05T02:43:27.492318Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":65,"content_modified":66},"NCT02523014","Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas",[64],"Phase 2","2026-08-26T02:16:38.897933Z","2026-05-05T02:43:27.482521Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT05894239","A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer",[20],"2026-08-26T02:17:30.145302Z","2026-05-05T02:43:27.447164Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT06982521","Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+\u002FHER2- Breast Cancer",[20],"2026-08-26T02:18:51.833592Z","2026-05-05T02:43:27.289440Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":84,"content_modified":85},"NCT05948943","Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.",[83],"Phase 2\u002FPhase 3","2026-08-26T02:17:07.954622Z","2026-05-05T02:43:27.289409Z",{"nct_id":87,"title":88,"phases":89,"status":13,"updated_at":90,"content_modified":91},"NCT07368998","To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer",[64],"2026-08-26T02:18:08.005333Z","2026-05-05T02:43:26.896844Z",{"nct_id":93,"title":94,"phases":95,"status":13,"updated_at":96,"content_modified":97},"NCT07054190","A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer",[64],"2026-08-26T02:15:03.757872Z","2026-05-05T02:35:31.905076Z",{"nct_id":99,"title":100,"phases":101,"status":13,"updated_at":102,"content_modified":103},"NCT06997588","EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)",[64],"2026-08-26T02:16:46.951087Z","2026-05-05T02:35:31.765926Z",{"nct_id":105,"title":106,"phases":107,"status":13,"updated_at":108,"content_modified":109},"NCT07174336","A Study of Tersolisib (LY4064809\u002FSTX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)",[20],"2026-08-26T02:19:22.562392Z","2026-04-29T02:57:57.088514Z",{"nct_id":111,"title":112,"phases":113,"status":13,"updated_at":114,"content_modified":115},"NCT06736704","SNV4818 in Participants With Advanced Solid Tumors",[27],"2026-08-26T02:19:05.360997Z","2026-04-29T02:57:57.076319Z",{"nct_id":117,"title":118,"phases":119,"status":13,"updated_at":120,"content_modified":121},"NCT05843253","Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant",[64],"2026-08-26T02:19:31.671303Z","2026-05-05T02:43:29.388169Z",{"nct_id":123,"title":124,"phases":125,"status":13,"updated_at":126,"content_modified":127},"NCT07383506","A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors",[12],"2026-08-26T02:18:14.396999Z","2026-05-05T02:43:29.192289Z",{"nct_id":129,"title":130,"phases":131,"status":13,"updated_at":132,"content_modified":133},"NCT06625775","Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors",[12],"2026-08-26T02:17:09.131534Z","2026-05-05T02:43:28.969601Z",{"nct_id":135,"title":136,"phases":137,"status":13,"updated_at":138,"content_modified":139},"NCT06789913","A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)",[64],"2026-08-26T02:17:21.315591Z","2026-07-05T05:32:16.695791Z",{"nct_id":141,"title":142,"phases":143,"status":13,"updated_at":144,"content_modified":145},"NCT07524322","Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors",[12],"2026-08-26T02:16:01.079019Z","2026-05-05T02:43:28.715467Z",{"nct_id":147,"title":148,"phases":149,"status":13,"updated_at":150,"content_modified":151},"NCT06993844","Phase 1\u002F2 Study of ETX-636 in Participants With Advanced Solid Tumors",[27],"2026-08-26T02:17:23.750999Z","2026-05-05T02:43:27.756864Z",{"nct_id":153,"title":154,"phases":155,"status":13,"updated_at":156,"content_modified":157},"NCT05039801","IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors",[12],"2026-08-26T02:18:49.989941Z","2026-04-29T02:57:57.070174Z",{"nct_id":159,"title":160,"phases":161,"status":13,"updated_at":162,"content_modified":163},"NCT07426822","Rash & Diarrhea Prophylaxis With Capivasertib",[64],"2026-08-26T02:18:01.700186Z","2026-05-05T02:43:28.658046Z",{"nct_id":165,"title":166,"phases":167,"status":13,"updated_at":168,"content_modified":169},"NCT05933395","Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4\u002F6 Inhibitor",[64],"2026-08-26T02:15:24.145250Z","2026-05-05T02:43:29.132138Z",{"nct_id":171,"title":172,"phases":173,"status":13,"updated_at":174,"content_modified":175},"NCT05307705","A Study of LOXO-783 in Patients With Breast Cancer\u002FOther Solid Tumors",[12],"2026-08-26T02:16:00.194860Z","2026-07-24T01:27:14.903653Z",{"nct_id":177,"title":178,"phases":179,"status":180,"updated_at":181,"content_modified":182},"NCT05563220","Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer",[27],"ACTIVE_NOT_RECRUITING","2026-08-03T02:12:21.768801Z","2026-05-05T02:43:29.025043Z",{"nct_id":184,"title":185,"phases":186,"status":180,"updated_at":187,"content_modified":188},"NCT06496568","A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab, and Inavolisib Plus Pembrolizumab in PIK3CA-Mutated Cancers",[12],"2026-08-03T03:39:05.349687Z","2026-05-05T02:43:28.201534Z"]